Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David Li
Observed name:
Li, David
Institution:
University of Chicago
Observed institutions:
University of Chicago,
Eisai (United States)
OpenAlex ID:
A5121297976
Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial
2025
·
Jin Zhou
, Erica Andreozzi
, et al.
·
Alzheimer s & Dementia
·
2
PDF
Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial
2025
·
Kristin R Wildsmith
, Arnaud Charil
, et al.
·
Alzheimer s & Dementia
·
2
PDF
A flexible and unified framework for single- and multi-outcome Mendelian randomization using summary statistics
2026
·
Bowei Kang
, David Li
, et al.
·
The American Journal of Human Genetics
Lecanemab Subcutaneous Formulation for Maintenance Dosing in Early Alzheimer’s Disease (AD)
2025
·
Larisa Reyderman
, Natasha Penner
, et al.
·
Alzheimer s & Dementia
PDF
Beyond A Single Study Visit: Lesson Learned from the AD Clinical Trials
2025
·
Jinglin Zhong
, David Li
, et al.
·
Alzheimer s & Dementia
PDF
DIAN‐TU‐001 Trial (Tau NexGen) Rationale and Enrollment Experience
2025
·
Lon S. S Schneider
, Jorge J. Llibre‐Guerra
, et al.
·
Alzheimer s & Dementia
PDF
Development of Subcutaneous Lecanemab: Establishing the Comparability of Subcutaneous and Intravenous Lecanemab Formulations
2025
·
Natasha Penner
, Sumit Rawal
, et al.
·
Alzheimer s & Dementia
PDF
Show more works
View as search
Works count:
8
Citation count:
4
H-index:
2
I10-index:
Year
Topic
Type
